Development of high-specific-activity 68Ga-labeled DOTA-rhenium-cyclized α-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors
Authors:
- 1 July 2009
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 36 (5) , 505-513
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The importance of high specific radioactivity in the performance of 68Ga-labeled peptideNuclear Medicine and Biology, 2008
- Gallium-68-labeled DOTA-rhenium-cyclized α-melanocyte-stimulating hormone analog for imaging of malignant melanomaNuclear Medicine and Biology, 2007
- 64Cu-Labeled Alpha-Melanocyte-Stimulating Hormone Analog for MicroPET Imaging of Melanocortin 1 Receptor ExpressionBioconjugate Chemistry, 2007
- Update : Renaissance of Targeting Molecules for MelanomaCancer Biotherapy and Radiopharmaceuticals, 2006
- Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analoguesNuclear Medicine and Biology, 2006
- False-negative findings in skin cancer and melanoma screeningJournal of the American Academy of Dermatology, 1995
- Metabolism of receptor targeted 111In-DTPA-glycoproteins: Identification of 111In-DTPA-ϵ-lysine as the primary metabolic and excretory productNuclear Medicine and Biology, 1994
- [111In]-DTPA-labeled analogues of α-melanocyte-stimulating hormone for melanoma targeting: Receptor bindingin vitro andin vivoInternational Journal of Cancer, 1994
- The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanomaBritish Journal of Radiology, 1992
- Application of microwave technology to the synthesis of short-lived radiopharmaceuticalsJournal of the Chemical Society, Chemical Communications, 1987